B. Riley analyst Mayank Mamtani raised the firm’s price target on Trevi Therapeutics (TRVI) to $20 from $11 and keeps a Buy rating on the ...

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Trevi Therapeutics (TRVI – Research Report), with ...

Hello, everyone, and welcome to MiNK Therapeutics fourth-quarter 2024 financial results call. Please note that this call is being recorded. (Operator Instructions) I'd now like to hand the call over ...

Trevi Therapeutics (TRVI) stock has rocketed up over 63% in the past week on news that recent clinical trials have shown promising results. The ...

B. Riley analyst Mayank Mamtani lowered the firm’s price target on Lineage Cell Therapeutics (LCTX) to $3 from $4 and keeps a Buy rating on the ...

Analysts expect the Nashville, Tennessee-based company to report a quarterly loss at 1 cent per share, versus a year-ago loss ...

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Cytokinetics (CYTK – Research Report), with a price target of $88.00. The company’s shares closed ...

B. Riley analyst Mayank Mamtani reiterates a Buy rating on Viking Therapeutics (VKTX) with a $96 price target after the company announced a “long-awaited” manufacturing agreement with ...

Mayank Mamtani; Analyst; B. Riley Securities, Inc. Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. (Operator Instructions) As a reminder ...

B. Riley analyst Mayank Mamtani reiterates a Buy rating on Viking Therapeutics (VKTX) with a $96 price target after the company announced a ...

Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. I will now turn the call ...